Treatment of Hepatitis C as Prevention: A Modeling Case Study in Vietnam

被引:37
作者
Durier, Nicolas
Chi Nguyen
White, Lisa J. [1 ,2 ]
机构
[1] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Clin Vaccinol & Trop Med, Oxford OX3 9DU, England
[2] Mahidol Univ, Fac Trop Med, Bangkok 10700, Thailand
来源
PLOS ONE | 2012年 / 7卷 / 04期
基金
英国惠康基金;
关键词
INJECTION-DRUG USERS; VIROLOGICAL RESPONSE; VIRUS-INFECTION; PLUS RIBAVIRIN; HEROIN USERS; THERAPY; REINFECTION; ONSET; HIV;
D O I
10.1371/journal.pone.0034548
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Treatment of hepatitis C (HCV) is very effective, achieving a cure in 50-90% of patients. Besides its own good for individuals, this most likely translates in reduced transmission, but this phenomenon has yet to be fully explored. Methods and Findings: In this mathematical modeling study done in the context of Vietnam, we estimated the public health benefit that HCV therapy for injecting drug users (IDUs) may achieve. Treatment coverage of 25, 50 and 75% of chronically HCV-infected IDUs (4 years into infection) is predicted to reduce the chronic HCV viremia prevalence respectively by 21, 37 and 50%, 11 years after full scale up to the intended coverage. At a constant 50% coverage level, earlier treatment, 3, 2, and 1 year into infection is predicted to reduce the chronic HCV viremia prevalence by 46, 60 and 85%. In these later 3 scenarios, for every 100 treatment courses provided, a total of respectively 50, 61 and 94 new infections could be averted. These benefits were projected in the context of current low coverage of methadone maintenance therapy and needles/ syringes exchange programs, and these services expansion showed complementary preventive benefits to HCV therapy. The program treatment commitment associated with the various scenarios is deemed reasonable. Our model projections are robust under adjustment for uncertainty in the model parameter values. Conclusions: In this case study in Vietnam, we project that treatment of HCV for injecting drug users will have a preventative herd effect in addition to curing patients in need for therapy, achieving a substantial reduction in HCV transmission and prevalence.
引用
收藏
页数:10
相关论文
共 35 条
  • [11] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Davis, GL
    Wong, JB
    McHutchison, JG
    Manns, MP
    Harvey, J
    Albrecht, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 645 - 652
  • [12] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
    Fried, MW
    Shiffman, ML
    Reddy, KR
    Smith, C
    Marinos, G
    Goncales, FL
    Haussinger, D
    Diago, M
    Carosi, G
    Dhumeaux, D
    Craxi, A
    Lin, A
    Hoffman, J
    Yu, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
  • [13] Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance
    Gerlach, JT
    Diepolder, HM
    Zachoval, R
    Gruener, NH
    Jung, MC
    Ulsenheimer, A
    Schraut, WW
    Schirren, CA
    Waechtler, M
    Backmund, M
    Pape, GR
    [J]. GASTROENTEROLOGY, 2003, 125 (01) : 80 - 88
  • [14] Diagnosis, Management, and Treatment of Hepatitis C: An Update
    Ghany, Marc G.
    Strader, Doris B.
    Thomas, David L.
    Seeff, Leonard B.
    [J]. HEPATOLOGY, 2009, 49 (04) : 1335 - 1374
  • [15] Adherence to treatment for recently acquired hepatitis C virus (HCV) infection among injecting drug users
    Grebely, Jason
    Matthews, Gail V.
    Hellard, Margaret
    Shaw, David
    van Beek, Ingrid
    Petoumenos, Kathy
    Alavi, Maryam
    Yeung, Barbara
    Haber, Paul S.
    Lloyd, Andrew R.
    Kaldor, John M.
    Dore, Gregory J.
    [J]. JOURNAL OF HEPATOLOGY, 2011, 55 (01) : 76 - 85
  • [16] Reinfection with hepatitis C virus following sustained virological response in injection drug users
    Grebely, Jason
    Knight, Elizabeth
    Ngai, Tyler
    Genoway, Krista A.
    Raffa, Jesse D.
    Storms, Michelle
    Gallagher, Lesley
    Krajden, Mel
    Dore, Gregory J.
    Duncan, Fiona
    Conway, Brian
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (07) : 1281 - 1284
  • [17] TRANSITIONS IN PATTERNS OF HEROIN ADMINISTRATION - A STUDY OF HEROIN CHASERS AND HEROIN INJECTORS
    GRIFFITHS, P
    GOSSOP, M
    POWIS, B
    STRANG, J
    [J]. ADDICTION, 1994, 89 (03) : 301 - 309
  • [18] Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
    Hadziyannis, SJ
    Sette, H
    Morgan, TR
    Balan, V
    Diago, M
    Marcellin, P
    Ramadori, G
    Bodenheimer, H
    Bernstein, D
    Rizzetto, M
    Zeuzem, S
    Pockros, PJ
    Lin, A
    Ackrill, AM
    [J]. ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) : 346 - 355
  • [19] Hepatitis C virus infection among injection drug users - Survival analysis of time to seroconversion
    Hagan, H
    Thiede, H
    Des Jarlais, DC
    [J]. EPIDEMIOLOGY, 2004, 15 (05) : 543 - 549
  • [20] Hepatitis C Treatment for Injection Drug Users: A Review of the Available Evidence
    Hellard, Margaret
    Sacks-Davis, Rachel
    Gold, Judy
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 49 (04) : 561 - 573